BBI-2779

Overview

BBI-2779 is a highly selective, orally active CHK1 inhibitor with a CHK1 IC 50 of 0.3 nM. BBI-2779 leverages transcription-replication conflicts on extrachromosomal DNA (ecDNA) to induce synthetic lethality, replication stress, DNA damage and cell death in ecDNA-positive tumor cells. BBI-2779 blocks ecDNA-mediated acquired resistance to targeted therapies and inhibits tumor growth in mouse models of gastric cancer . BBI-2779 is applicable to ecDNA-positive cancer-related research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Checkpoint Kinase (Chk)

Product Information

• Catalog No.: HY-155798
• CAS No.: 2871057-47-3
• Molecular Formula: C19H19N7O2
• Molecular Weight: 377.40
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source